Vicore Pharma Holding AB American Depositary Shares (VCRE)
Stock · NASDAQ · Health Care
$8.98as of 10/16/2026
Price chart
Active signals
No technical signal is currently active for this symbol.
Resistance level
$11.46
Industry
Biotechnology: Pharmaceutical Preparations
About VCRE
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 46
- Website
- vicorepharma.com/
Fundamentals
- 1-day range
- $8.93$9.3
- Market cap
- $3.33B
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-1.91
- Dividend yield
- —
- Beta
- 0.60
- Avg. volume
- 17.4K
52-week range
$8.56$18.24
Forecasts
2 analyst ratings
Buy 92%
Hold 8%
Sell 0%
1-year price forecast
High
$33.33
+271.1%
Median
$29.23
+225.5%
Low
$25.14
+179.9%
Vicore Pharma Holding AB American Depositary Shares Competitors
Chosen by industry and closest market cap.
- VCREVicore Pharma Holding AB American Depositary Shares$8.98▼ 1.21%Market cap $3.33BP/E —$8.56$18.24
- ARQTArcutis Biotherapeutics Inc. Common Stock$28.82▼ 0.96%Market cap $3.31BP/E 128.52$19.3$31.77
- NAMSNewAmsterdam Pharma Company N.V. Ordinary Shares$19.83▼ 3.83%Market cap $3.23BP/E —$20.91$42.21
- MBXMBX Biosciences Inc. Common Stock$49.61▼ 2.17%Market cap $3.19BP/E —$12.94$72.64
- IDYAIDEAYA Biosciences Inc. Common Stock$32.85▼ 2.95%Market cap $3.50BP/E —$26.44$42.68
- QUREuniQure N.V. Ordinary Shares$21.78▼ 3.29%Market cap $3.15BP/E —$8.73$71.5
- ALMSAlumis Inc. Common Stock$6.12▼ 3.01%Market cap $3.54BP/E —$4.37$31.35
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| VCRE Vicore Pharma Holding AB American Depositary Shares | $3.33B | — | $8.98 | ▼ 1.21% | $8.56$18.24 |
| ARQT Arcutis Biotherapeutics Inc. Common Stock | $3.31B | 128.52 | $28.82 | ▼ 0.96% | $19.3$31.77 |
| NAMS NewAmsterdam Pharma Company N.V. Ordinary Shares | $3.23B | — | $19.83 | ▼ 3.83% | $20.91$42.21 |
| MBX MBX Biosciences Inc. Common Stock | $3.19B | — | $49.61 | ▼ 2.17% | $12.94$72.64 |
| IDYA IDEAYA Biosciences Inc. Common Stock | $3.50B | — | $32.85 | ▼ 2.95% | $26.44$42.68 |
| QURE uniQure N.V. Ordinary Shares | $3.15B | — | $21.78 | ▼ 3.29% | $8.73$71.5 |
| ALMS Alumis Inc. Common Stock | $3.54B | — | $6.12 | ▼ 3.01% | $4.37$31.35 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Jefferies Initiates Coverage On Vicore Pharma Holding with Buy Rating, Announces Price Target of $25Benzinga · 10/9/2026
- 12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga · 10/1/2026
- 12 Health Care Stocks Moving In Wednesday's After-Market SessionBenzinga · 9/30/2026
- Increase in Number of Shares and Votes in Vicore PharmaYahoo · 9/30/2026
- Vicore Pharma to Present in The Stifel 2026 Virtual Immunology and Inflammation ForumYahoo · 9/17/2026
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Jefferies initiates coverage of Vicore Pharma, sets $25 target
Jefferies has started coverage of Vicore Pharma Holding and issued a price target of $25 per share. The firm’s view adds a new analyst perspective to the market. The stock is currently trading near its long‑term support around $11.12 and its RSI is in the low‑30s, indicating limited upward momentum. The price target is notably higher than recent trading levels.
Jefferies initiates coverage of Vicore Pharma, sets $25 target. Jefferies has started coverage of Vicore Pharma Holding and issued a price target of $25 per share. The firm’s view adds a new analyst perspective to the market. The stock is currently trading near its long‑term support around $11.12 and its RSI is in the low‑30s, indicating limited upward momentum. The price target is notably higher than recent trading levels.